publication date: Feb. 3, 2014


CCL37-01c.html

Breast Cancer
Long-term Follow-up Shows ADH and ALH Tissue Abnormalities Can Carry Similar Risk

Contrary to existing understanding, long-term follow-up of patients with two types of breast tissue abnormalities suggests that both types of abnormalities have the same potential to progress to breast cancer.

The study, published in Cancer Prevention Research, a journal of the American Association for Cancer Research, challenges current understanding that atypical ductal hyperplasia leads to breast cancer in the same breast, while atypical lobular hyperplasia may not be a direct precursor of breast cancer, but may indicate equal risk of breast cancer across both breasts.

“Ours is the first report with sufficient numbers of both types of atypia and long-term follow-up for breast cancers that compared the side of breast that had atypia with the side of breast in which cancer arose and the timeframe when the cancers developed,” said Lynn Hartmann, professor of oncology at the Mayo Clinic. “We showed that even though the two types of atypia look different histologically, they behave quite similarly in terms of what happens to patients.”

Hartmann and colleagues identified 698 women from the Mayo Benign Breast Disease Cohort who had biopsy-confirmed atypia; 330 of them had ADH, 327 had ALH, and 32 had both. The investigators followed these women for an average of 12.5 years, and 143 of them developed breast cancer.

The investigators found that the ratio of breast cancer in the same breast in which the atypia was detected versus in the opposite breast was the same, 2:1, for both ADH and ALH.

A similar number of women with either ADH or ALH developed breast cancer … Continue reading CCL Jan – Breast Cancer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.